Business
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program to be presented at TRP in November; additional programs planned for 2026, including MP0726 targeting mesothelin. Updated data from Phase 1/2a trial of MP0533, a multispecific T cell engager for AML, to be presented at ASH in December Protocol approved for Phase
About this update from Molecular Partners Ag
[{"type":"image","alt":"Molecular Partners","displaySize":"","headline":null,"caption":"Molecular Partners","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_O68YKj8eCWCeSjo6zZBpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa","width":300,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 ","length":177,"tagName":"p"}]},{"val":[{"type":"text","content":"First patient images from MP0712 compassionate care program to be presented at TRP in November; additional programs planned for 2026, including MP0726 targeting mesothelin. ","length":172,"tagName":"p"}]},{"val":[{"type":"text","content":"Updated data from Phase 1/2a trial of MP0533, a multispecific T cell engager for AML, to be presented at ASH in December ","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Protocol approved for Phase 2 investigator-initiated trial of FAP x CD40 agonist MP0317","length":87,"tagName":"p"}]},{"val":[{"type":"text","content":"Strong financial position with cash runway until 2028","length":53,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":609,"olType":false},{"type":"text","content":"ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced corporate highlights and unaudited financial results for the third quarter of 2025.","length":431,"tagName":"p"},{"type":"text","content":"“We are excited to present initial clinical imaging data this November on MP0712, the 1st Radio-DARPin targeting DLL3, from compassionate care use in South Africa. The IND application for MP0712 has been filed and we see the alpha-targeting approaches for DLL3 in lung cancer as a valuable new modality for patients. Buildi...